SGLTR TABLET contains Remogliflozin which belongs to the group of medicines called Anti-diabetic agents. SGLTR TABLET is used to manage type 2 diabetes when diet and exercise alone are insufficient to provide adequate glycaemic control in adult patients.
SGLTR TABLET is also used as a combination therapy with metformin, when both metformin therapy and diet & exercise are inadequate provide glycaemic control in affected individuals.
SGLTR TABLET is not recommended for use in patients allergic to Remogliflozin. It is also not recommended for use in patients with liver problems (such as moderate to severe liver impairment), and/or kidney problems (such as moderate to severe renal impairment).
Before taking [GBKEYWORD], inform your doctor if you have type 1 diabetes, dehydration (associated with symptoms such as nausea, vomiting, and/or loss of excessive fluid from the body), and/or low blood pressure.
SGLTR TABLET is not recommended for use during pregnancy and in women planning for pregnancy. It is also not recommended for use in breastfeeding women since it is not known whether the medicine may pass through breast milk.
SGLTR TABLET is not recommended for use in children and adolescents (aged below 18 years). It is also not recommended for use in elderly patients (aged 75 years/above). Consult your doctor before taking the medicine.
The most common side effects of taking SGLTR TABLET are constipation, diarrhoea, weakness, fever, chills, urinary tract infection, and/or headache. Consult your doctor if any of these symptoms worsens.
No content available
